Akebia Therapeutics Inc. (AKBA)
NASDAQ: AKBA
· Real-Time Price · USD
2.44
-0.11 (-4.31%)
At close: May 12, 2025, 3:59 PM
2.45
0.62%
Pre-market: May 13, 2025, 04:12 AM EDT
Akebia Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| License Collaboration And Other Revenue Revenue | 8M | 24.32M | 177.07M | 142.22M | 166.41M | 223.88M | 200.47M |
| License Collaboration And Other Revenue Revenue Growth | -67.11% | -86.26% | +24.51% | -14.54% | -25.67% | +11.68% | n/a |
| Product Revenue | 152.18M | 170.3M | n/a | n/a | 128.9M | 111.12M | n/a |
| Product Revenue Growth | -10.64% | n/a | n/a | n/a | +16.00% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 27.68M | 26.52M | 27.68M | 26.15M | 26.29M | 22.71M | 27.04M | 25.22M | 31.5M | 31.66M | 33.7M | 45.02M | 44.83M | 47.23M | 42.55M | 42.02M | 40.31M | 40.88M | 36.53M | 38.66M | 44.92M | 34.18M | 36.96M | 34.29M | 55.12M | 10.38M | 12.54M | 9.02M | 7.57M | 6.75M | 6.91M | 5.79M | 6.14M | 4.94M | 5.31M | 5.81M | 7.51M | 3.89M | 3.71M | 3.39M |
| Selling, General, and Administrative Revenue Growth | +4.37% | -4.20% | +5.85% | -0.54% | +15.76% | -16.00% | +7.20% | -19.93% | -0.51% | -6.05% | -25.14% | +0.42% | -5.09% | +11.00% | +1.24% | +4.25% | -1.39% | +11.92% | -5.52% | -13.93% | +31.42% | -7.53% | +7.79% | -37.79% | +431.13% | -17.23% | +38.94% | +19.25% | +12.14% | -2.27% | +19.30% | -5.79% | +24.27% | -6.91% | -8.60% | -22.63% | +93.18% | +4.88% | +9.32% | n/a |
| Research and Development Revenue | 11.79M | 8.49M | 7.25M | 9.37M | 9.47M | 13.33M | 20.2M | 19.69M | 31.9M | 27.35M | 26.03M | 43.83M | 29.56M | 40.47M | 37.21M | 40.61M | 37.58M | 46.86M | 52.82M | 81.23M | 80.41M | 74.51M | 85.69M | 82.35M | 87.11M | 70.63M | 71.92M | 61.4M | 68.38M | 58.71M | 43.75M | 60.05M | 33.44M | 31.24M | 30.88M | 20.23M | 12.54M | 15.79M | 7.18M | 7.5M |
| Research and Development Revenue Growth | +38.87% | +17.09% | -22.62% | -1.11% | -28.94% | -34.00% | +2.60% | -38.30% | +16.65% | +5.08% | -40.62% | +48.30% | -26.97% | +8.75% | -8.36% | +8.07% | -19.80% | -11.29% | -34.98% | +1.02% | +7.92% | -13.05% | +4.06% | -5.47% | +23.33% | -1.78% | +17.12% | -10.20% | +16.47% | +34.19% | -27.14% | +79.60% | +7.03% | +1.17% | +52.59% | +61.38% | -20.59% | +119.86% | -4.30% | n/a |